A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases

References

• Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–425. doi:10.1038/nrc3055
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Wade SW, Reich A, et al. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18(1):44. doi:10.1186/s12885-017-3922-0
   PubMedGoogle Scholar
• Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865–873. doi:10.1016/S0002-9440(10)65628-3
   PubMed Web of Science ®Google Scholar
• Chaffer CL, San Juan BP, Lim E, et al. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645–654. doi:10.1007/s10555-016-9648-7
   PubMed Web of Science ®Google Scholar
• Macedo F, Ladeira K, Pinho F, et al. Bone metastases: an overview. Oncol Rev. 2017;11(1):321. doi:10.4081/oncol.2017.321
   PubMed Web of Science ®Google Scholar
• Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer. 2016;16(6):373–386. doi:10.1038/nrc.2016.44
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Bozec A, Rauner M, et al. Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol. 2021;18(8):488–505. doi:10.1038/s41571-021-00499-9
   PubMed Web of Science ®Google Scholar
• Wortzel I, Dror S, Kenific CM, et al. Exosome-mediated metastasis: communication from a distance. Dev Cell. 2019;49(3):347–360. doi:10.1016/j.devcel.2019.04.011
   PubMed Web of Science ®Google Scholar
• Paiva AE, Lousado L, Guerra DAP, et al. Pericytes in the premetastatic niche. Cancer Res. 2018;78(11):2779–2786. doi:10.1158/0008-5472.CAN-17-3883
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–458. doi:10.1038/nrc1098
   PubMed Web of Science ®Google Scholar
• Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328(3):679–687. doi:10.1016/j.bbrc.2004.11.070
   PubMed Web of Science ®Google Scholar
• Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact. 2002;2(6):570–572.
   PubMedGoogle Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–593. doi:10.1038/nrc867
   PubMed Web of Science ®Google Scholar
• Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80(8 Suppl):1546–1556.
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102. doi:10.1038/nature09387
   PubMed Web of Science ®Google Scholar
• Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–iii137. doi:10.1093/annonc/mdu103
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American society of clinical oncology-cancer care Ontario focused guideline update. J Clin Oncol. 2017;35(35):3978–3986. doi:10.1200/JCO.2017.75.4614
   PubMed Web of Science ®Google Scholar
• Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;2002(2):CD002068. doi:10.1002/14651858.CD002068
   PubMedGoogle Scholar
• Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 2009;10(10):1478–1487. doi:10.1002/jbmr.5650101008
   Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80–100. doi:10.1210/edrv.19.1.0325
   PubMed Web of Science ®Google Scholar
• Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–419. doi:10.1038/nrd3705
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–2621. doi:10.1002/cncr.20308
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 2003;21(16):3150–3157. doi:10.1200/JCO.2003.04.105
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822. doi:10.1016/S0140-6736(10)62344-6
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body -J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139. doi:10.1200/JCO.2010.29.7101
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–1132. doi:10.1200/JCO.2010.31.3304
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339–351. doi:10.1016/S1470-2045(18)30862-3
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–443. doi:10.1016/S0140-6736(15)60995-3
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17. doi:10.1016/j.bone.2017.08.003
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755. doi:10.1056/NEJMoa0809003
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46. doi:10.1016/S0140-6736(11)61226-9
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823–1829. doi:10.1097/JTO.0b013e31826aec2b
   PubMed Web of Science ®Google Scholar
• Michael Gnant MD, Frantal S, Pfeiler G, et al. Long-term outcomes of adjuvant denosumab in breast cancer. NEJM. 2022;12(1):EVIDoa2200162.
   Google Scholar
• von Moos R, Lewis K, Massey L, et al. Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe. Bone. 2022;154:116243. doi:10.1016/j.bone.2021.116243
   PubMed Web of Science ®Google Scholar
• Coleman R, Hadji P, Body -J-J, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1650–1663. doi:10.1016/j.annonc.2020.07.019
   PubMed Web of Science ®Google Scholar
• Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res. 2006;12(20):6231s–6235s. doi:10.1158/1078-0432.CCR-06-0682
   PubMed Web of Science ®Google Scholar
• Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126(3):547–557. doi:10.1016/j.radonc.2018.01.003
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Hopkins K, Misra V, et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322(21):2084–2094. doi:10.1001/jama.2019.17913
   PubMed Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–4459. doi:10.1158/1078-0432.CCR-04-2244
   PubMed Web of Science ®Google Scholar
• Coleman R. Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med. 2016;46(2):99–104. doi:10.1053/j.semnuclmed.2015.10.012
   PubMed Web of Science ®Google Scholar
• Sousa S, Clezardin P. Bone-targeted therapies in cancer-induced bone disease. Calcif Tissue Int. 2018;102(2):227–250. doi:10.1007/s00223-017-0353-5
   PubMed Web of Science ®Google Scholar
• Parker C, Lewington V, Shore N, et al. Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol. 2018;4(12):1765–1772. doi:10.1001/jamaoncol.2018.4044
   PubMed Web of Science ®Google Scholar
• Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400. doi:10.1016/S1470-2045(05)70206-0
   PubMed Web of Science ®Google Scholar
• Garg AK, Shiu AS, Yang J, et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer. 2012;118(20):5069–5077. doi:10.1002/cncr.27530
   PubMed Web of Science ®Google Scholar
• Gerszten PC, Burton SA, Ozhasoglu C, et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine. 2007;32(2):193–199. doi:10.1097/01.brs.0000251863.76595.a2
   PubMed Web of Science ®Google Scholar
• Bishop AJ, Tao R, Guadagnolo BA, et al. Spine stereotactic radiosurgery for metastatic sarcoma: patterns of failure and radiation treatment volume considerations. J Neurosurg Spine. 2017;27(3):303–311. doi:10.3171/2017.1.SPINE161045
   PubMed Web of Science ®Google Scholar
• Yamada Y, Katsoulakis E, Laufer I, et al. The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery. Neurosurg Focus. 2017;42(1):E6. doi:10.3171/2016.9.FOCUS16369
   PubMed Web of Science ®Google Scholar
• Jhaveri PM, Teh BS, Paulino AC, et al. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases. Acta Oncol. 2012;51(5):584–588. doi:10.3109/0284186X.2011.652741
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hyman DM, Davids MS, et al. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078–1088. doi:10.1016/S0140-6736(20)30164-1
   PubMed Web of Science ®Google Scholar
• Carducci MA, Saad F, Abrahamsson P-A, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959–1966. doi:10.1002/cncr.22996
   PubMed Web of Science ®Google Scholar
• Nelson JB, Fizazi K, Miller K, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012;118(22):5709–5718. doi:10.1002/cncr.27674
   PubMed Web of Science ®Google Scholar
• Gnant M, Baselga J, Rugo HS, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105(9):654–663. doi:10.1093/jnci/djt026
   PubMedGoogle Scholar
• Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17(3):279–288. doi:10.1016/j.neo.2015.01.005
   PubMed Web of Science ®Google Scholar
• Bertoldo F, Silvestris F, Ibrahim T, et al. Targeting bone metastatic cancer: role of the mTOR pathway. Biochim Biophys Acta. 2014;1845(2):248–254. doi:10.1016/j.bbcan.2014.01.009
   PubMed Web of Science ®Google Scholar
• Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol. 2018;36(8):765–772. doi:10.1200/JCO.2017.74.7352
   PubMed Web of Science ®Google Scholar
• Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos Int. 2015;26(2):699–712. doi:10.1007/s00198-014-2944-6
   PubMed Web of Science ®Google Scholar
• Bukowska B, Gajek A, Marczak A. Two drugs are better than one. A short history of combined therapy of ovarian cancer. Contemp Oncol. 2015;19(5):350–353.
   Google Scholar
• Palmer AC, Chidley C, Sorger PK. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. Elife. 2019;8:e50036.
   PubMed Web of Science ®Google Scholar
• Cursano MC, Iuliani M, Casadei C, et al. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: a review. Crit Rev Oncol Hematol. 2020;146:102864. doi:10.1016/j.critrevonc.2020.102864
   PubMed Web of Science ®Google Scholar
• Tanaka H, Makita C, Manabe Y, et al. Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. J Radiat Res. 2020;61(3):494–498. doi:10.1093/jrr/rraa020
   PubMed Web of Science ®Google Scholar
• Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:227. doi:10.3389/fmed.2017.00227
   PubMed Web of Science ®Google Scholar
• Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79–92. doi:10.1038/s41585-020-00400-w
   PubMed Web of Science ®Google Scholar
• Chmielik E, Rusinek D, Oczko-Wojciechowska M, et al. Heterogeneity of thyroid cancer. Pathobiology. 2018;85(1–2):117–129. doi:10.1159/000486422
   PubMed Web of Science ®Google Scholar
• Beksac AT, Paulucci DJ, Blum KA, et al. Heterogeneity in renal cell carcinoma. Urol Oncol. 2017;35(8):507–515. doi:10.1016/j.urolonc.2017.05.006
   PubMed Web of Science ®Google Scholar
• Futakuchi M, Fukamachi K, Suzui M. Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv Drug Deliv Rev. 2016;99(20):206–211. doi:10.1016/j.addr.2015.11.017
   PubMedGoogle Scholar
• Xu X, Hou Y, Yin X, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012;148(5):886–895. doi:10.1016/j.cell.2012.02.025
   PubMed Web of Science ®Google Scholar
• Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–94. doi:10.1038/nature09807
   PubMed Web of Science ®Google Scholar
• Francis JM, Zhang C-Z, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4(8):956–971. doi:10.1158/2159-8290.CD-13-0879
   PubMed Web of Science ®Google Scholar
• Han Y, Wang D, Peng L, et al. Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis. J Hematol Oncol. 2022;15(1):59. doi:10.1186/s13045-022-01280-w
   PubMed Web of Science ®Google Scholar
• Ling A, Gruener RF, Fessler J, et al. More than fishing for a cure: the promises and pitfalls of high throughput cancer cell line screens. Pharmacol Ther. 2018;191:178–189. doi:10.1016/j.pharmthera.2018.06.014
   PubMed Web of Science ®Google Scholar
• Holbeck SL, Camalier R, Crowell JA, et al. The national cancer institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Res. 2017;77(13):3564–3576. doi:10.1158/0008-5472.CAN-17-0489
   PubMed Web of Science ®Google Scholar
• Jaaks P, Coker EA, Vis DJ, et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. 2022;603(7899):166–173. doi:10.1038/s41586-022-04437-2
   PubMed Web of Science ®Google Scholar
• Zagidullin B, Aldahdooh J, Zheng S, et al. DrugComb: an integrative cancer drug combination data portal. Nucleic Acids Res. 2019;47(W1):W43–W51. doi:10.1093/nar/gkz337
   PubMed Web of Science ®Google Scholar
• Yu C, Mannan AM, Yvone GM, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016;34(4):419–423. doi:10.1038/nbt.3460
   PubMed Web of Science ®Google Scholar
• Hirt CK, Booij TH, Grob L, et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy. Cell Genom. 2022;2(2):100095. doi:10.1016/j.xgen.2022.100095
   PubMedGoogle Scholar
• Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821. doi:10.1126/science.1225829
   PubMed Web of Science ®Google Scholar
• Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911. doi:10.1038/s41467-018-04252-2
   PubMedGoogle Scholar
• Qi LS, Larson M, Gilbert L, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–1183. doi:10.1016/j.cell.2013.02.022
   PubMed Web of Science ®Google Scholar